There is limited information regarding the immunological predictors of post-allogeneic stem cell transplant (alloSCT) outcome in chronic lymphocytic leukaemia (CLL), such as mixed T-cell chimerism. We analysed 143 consecutive patients with relapsed/refractory CLL, transplanted between 2000 and 2012, to determine the prognostic relevance of mixed chimerism post-alloSCT and the ability of post-transplant immunomodulation to treat relapse. Mixed T-cell chimerism occurred in 50% of patients at 3 months and 43% at 6 months post-alloSCT; upon 3-and 6-month landmark analysis, this was associated with inferior progression-free survival (PFS) [Hazard ratio (HR) 1Á93, P = 0Á003 and HR 2Á58, P < 0Á001] and survival (HR 1Á66, P = 0Á05 and HR 2Á17, P < 0Á001), independent of baseline patient characteristics, and a lower rate of grade II-IV acute graft-versushost disease (GHVD) (16% vs. 52%, P < 0Á001). Thirty-three patients were treated with immunomodulation for relapse post-alloSCT (immunosuppression withdrawal, n = 6, donor lymphocyte infusion, n = 27); 17 achieved complete response (CR), which predicted superior PFS (53 months vs. 10 months, P < 0Á001) and survival (117 months vs. 30 months, P = 0Á006). Relapsed patients with mixed chimerism had inferior response to immunomodulation; conversion to full donor chimerism was highly correlated both with CR and with the development of severe acute GVHD, which was fatal in 3/8 patients. Novel therapeutic strategies are required for patients with mixed T-cell chimerism post-alloSCT for CLL.
Long-term progression-free survival (PFS) is achieved in approximately 36-43% of patients receiving reduced-intensity conditioned allogeneic stem cell transplant (alloSCT) for CLL (Sorror et al, 2008; Dreger et al, 2010; Khouri et al, 2011; Brown et al, 2013) . AlloSCT has been demonstrated to overcome the adverse prognostic impact of high-risk genetic features, including del(17p) (Schetelig et al, 2008; Dreger et al, 2010) and TP53, NOTCH1 and SF3B1 mutations (Dreger et al, 2013) . There is evidence of a "graft-versus-leukaemia (GVL)" effect (Ben-Bassat et al, 2007; Delgado et al, 2009; Nishida et al, 2009 ); higher relapse rates are seen after T-cell depleted transplants (Dreger et al, 2010) and donor lymphocyte infusions (DLI) can induce durable complete remissions (Dreger et al, 2010; Khouri et al, 2011) .
There is limited data on the importance of mixed T-cell chimerism post-alloSCT in CLL. Mixed chimerism results from a state of bi-directional tolerance and is associated with higher relapse rates in Hodgkin lymphoma (Peggs et al, 2004 (Peggs et al, , 2011 and Follicular lymphoma (Thomson et al, 2010) , probably due to an ineffective GVL effect. Full donor chimerism can be induced with DLI (Thomson et al, 2010; Peggs et al, 2011) , with a correspondingly lower-than-expected relapse risk. We have previously reported that mixed T-cell chimerism (defined as ≤95% donor T-cells in peripheral blood) at 3 months is associated with higher relapse rate in a much smaller group of patients (Khouri et al, 2007) ; several other small studies have also demonstrated that mixed T-cell chimerism at earlier timepoints is associated with higher relapse risk (Jones et al, 2010; Shaffer et al, 2013) . Most of our patients received non-myeloablative conditioning and many received in-vivo T-cell depletion with alemtuzumab or anti-thymocyte globulin (ATG); both are associated with high-rates of mixed chimerism. We sought to determine whether mixed T-cell chimerism (hereafter referred to as mixed chimerism) post-transplant is associated with higher relapse rates and inferior survival in a large cohort of CLL patients.
Methods
We retrospectively analysed data from 143 consecutive patients transplanted between 2000 and 2012. Patients with Richter Transformation or receiving their second or subsequent alloSCT were excluded. The study was approved by the MD Anderson Cancer Center Institutional Review Board.
Statistical analysis was performed using R 3.0.3, SPSS version 22 (IBM Corp, Armonk, NY, USA) and GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA, USA). Descriptive statistics were used to summarise baseline characteristics. Univariate analyses (UVA) for binary variables were compared using Student's t test or v 2 tests as appropriate and multivariate analysis (MVA) was performed using logistic regression. Chimerism analysis was routinely performed at 1, 3 and 6 months post-alloSCT on peripheral blood (with myeloid and T lineage cell sorting) and as clinically indicated, through analysis of DNA microsatellite polymorphisms by polymerase chain reaction.
To assess the effect of mixed chimerism on outcome, landmark PFS and survival analyses were performed from the time of chimerism assessment (3 months and 6 months post-transplant), using the Kaplan-Meier method. The effect of mixed chimerism on PFS was assessed using the log-rank test. PFS was defined as the time from transplant to death or clinical disease progression requiring additional therapy, including DLI. The use of DLI to treat mixed chimerism or minimal residual disease, in the absence of clinical progression, was not considered to constitute an event in PFS analysis. MVA using Cox regression was performed with the addition of fixed pre-treatment patient and transplant characteristics as co-variates. Pre-treatment characteristics were included in the MVA model if P-values in UVA were <0Á1 in unadjusted analysis. Del(17p) was not included in MVA for the following reasons: fluorescent in situ hybridization was only available during the later time period covered by this study; del(17p) has previously not been shown to be associated with survival outcomes after transplant.
Cumulative incidences of relapse and treatment-related mortality (TRM) were assessed according to the cumulative incidence method and treated as competing risks. Acute and chronic GVHD incidences were also assessed according to the cumulative incidence method, with death and relapse considered competing risks.
Stem cell source, preparative regimens and posttransplant immunosuppressive regimens Transplant characteristics are shown in Table I . Most (n = 128) patients received non-myeloablative conditioning, predominantly with fludarabine, cyclophosphamide and rituximab-based preparative regimens; 15 patients received more intensive, myeloablative conditioning. All-but-two patients received calcineurin inhibitor-based immunosuppression for graft-versus-host disease (GVHD) prophylaxis (Khouri et al, 2011) ; 86/143 patients received in vivo T-cell depletion with ATG (n = 46) or alemtuzumab (n = 40); this was stem cell source-specific: 81/90 (90%) patients receiving transplants from unrelated donors, mismatched-related donors or umbilical cord blood transplants received in vivo T-cell depletion.
Results
Pre-transplant patient characteristics are shown in Table II . Median follow-up in surviving patients was 66 months (range 37-155).
Engraftment
Successful engraftment occurred in 137/139 evaluable patients. Median time to neutrophil engraftment (absolute neutrophil count >0Á5 9 10 9 /l) was 11 days (range 0-32) and median time to platelet engraftment (first day of an untransfused platelet count >20 9 10 9 /l for ≥3 days) was 9 days (range 0-106). Secondary graft loss occurred in 12 patients for the following reasons: donor cell rejection, 8; drugs, 1; viral infection, 2; persistent disease, 1. Six patients had a second transplant; two achieved long-term CR; the remaining four patients died from TRM. Of the six patients not receiving second transplants, two died from sepsis/marrow failure; the remaining four patients had autologous reconstitution of haematopoiesis and received alternative treatment for their residual CLL.
Response rates
Response to most recent pre-transplant therapy was: complete response (CR) in 6% and partial response (PR) in 50%; 44% of patients were refractory. Best response post-transplant was CR in 80/133 evaluable patients (60%); 31 (23%) achieved PR. Ten patients were not evaluable due to early death.
Cumulative incidences of acute GVHD, chronic GVHD TRM and relapse
Cumulative incidence of acute grade II-IV GVHD was 37Á7%; no new cases were observed beyond 5Á7 months in the absence of DLI. Cumulative incidence of chronic GHVD was 51Á7%. Cumulative incidences of TRM were 11Á1% at day 100, 23Á8% at 1 year and 33Á7% at 5 years. Cumulative incidences of relapse (CIR) were 6Á3% at 100 days, 26Á0% at 1 year and 44Á4% at 5 years. Only two relapses were seen beyond 5 years. Associations between baseline variables, cumulative incidences of TRM (CITRM) and relapse are shown in Fig 1. On MVA, myeloablative conditioning was significantly associated with lower CIR (P = 0Á04), offset by a higher CITRM (P = 0Á03). Sibling donor transplants were associated with reduced CITRM (P = 0Á007). Mixed chimerism at 3 and 6 months was associated with significantly increased CIR (P < 0Á001 and P = 0Á004, respectively), but no difference in CITRM (P = 0Á23 and P = 0Á77, respectively).
PFS, survival and causes of death
Median PFS for the total cohort was 12Á4 months [95% confidence interval (CI) 8Á3-16Á5]; 5-year PFS was 22Á1% (95% CI 15Á0-29Á2%). Univariate associations between pretransplant characteristics and PFS are shown in Table SI Table SIII . On MVA (Table SIV) , only B2M ≥ 4Á0 [HR 1Á78 (1Á11-2Á85), P = 0Á02] was significantly associated with survival. There was a trend toward superior survival in patients <60 years of age [HR 0Á67 (0Á43-1Á04), P = 0Á08]. Median survival for the total cohort was 42Á2 months (95% ATG, anti-thymocyte globulin; BEAM, carmustine, etoposide, cytarabine and melphalan; FBR, fludarabine, bendamustine and rituximab; FC, fludarabine and cyclophosphamide; FCR, fludarabine, cyclophosphamide and rituximab; Flu-Mel, fludarabine and melphalan; TBI, total body irradiation. TLI, total lymphoid irradiation; UCBT, umbilical cord blood transplantation. (11q) 14 (9Á8) del (17p) 30 (21Á0) Median number of prior therapies (range) 3 (1-10) Refractory to most recent prior therapy 65 (45Á5) Bulky lymphadenopathy (≥5 cm), n = 142
116 Cumulative incidences of relapse and treatment-related mortality (TRM), according to: (A) transplant from sibling donor or not; receiving a sibling donor transplant was associated with a significantly lower incidence of TRM (P = 0Á006); (B) myeloablative versus reduced-intensity conditioning; receiving myeloablative conditioning was associated with a significantly lower cumulative incidence of relapse (P = 0Á04), but a higher cumulative incidence of TRM (P = 0Á001); (C) complex karyotype (CKT) versus not; patients with CKT showed a trend toward a higher incidence of relapse (P = 0Á07); (D) receipt of alemtuzumab as the last treatment prior to transplant; there was a trend toward higher TRM (P = 0Á13) in patients receiving alemtuzumab as their last treatment prior to transplant; (E, F) the presence or absence of mixed T-cell chimerism at 6 and 3 months post-transplant; mixed chimerism post-transplant at 6 and 3 months was associated with a higher incidence of relapse (P = 0Á004 and 0Á0005, respectively), but no difference in TRM.
CI 21Á4-63Á0); 5 year survival was 42Á6% (95% CI 34Á2-51Á0%). Primary causes of death were as follows: disease recurrence or Richter Transformation, n = 33 (36Á3%); acute or chronic GVHD, n = 27 (29Á7%); infection, n = 15 (16Á5%); second cancer, n = 4 (4Á4%); organ failure, n = 3 (3Á3%); other, n = 9 (9Á9%).
T-cell Chimerism results, 3-and 6-month landmark PFS and survival analyses
At 3 months, 55/110 (50%) had mixed chimerism. Mixed chimerism was defined as ≤95% donor T-cells present by microsatellite polymorphism analysis performed on CKT was associated with a high incidence of early disease progression but no survival difference. PFS (C) and survival (D) according to whether alemtuzumab was given as the most recent anti-leukaemic therapy prior to transplant or not. Use of alemtuzumab as the most recent pre-transplant therapy was associated with inferior PFS and survival. PFS (E) and survival (F) according to baseline b 2 -microglobulin. Pre-transplant B2M ≥ 4Á0 mg/l was associated with inferior PFS and survival.
Mixed chimerism and relapse risk after alloSCT for CLL ª 2017 John Wiley & Sons Ltd peripheral blood, enriched for CD3+ cells (Khouri et al, 2007) . Pre-transplant variables associated with mixed chimerism on UVA are shown in Table SV . On MVA, receiving alemtuzumab-based therapy for treatment of CLL as the last treatment prior to transplant was associated with a significantly higher likelihood of mixed chimerism at 3 months [HR 3Á69 (1Á09-12Á54), P = 0Á036]. B2M ≥ 4Á0 mg/l was associated with a trend toward increased likelihood of mixed chimerism [HR 2Á83 (0Á97-8Á27), P = 0Á06]. Pre-transplant variables associated with mixed chimerism at 6 months on UVA are shown in Table SVI . On MVA, only receiving in vivo T-cell depletion as part of transplant conditioning was significantly associated with a higher incidence of mixed chimerism at 6 months [HR 2Á64 (1Á06-6Á59), P = 0Á04]. Univariate and multivariate associations between baseline characteristics, mixed chimerism, PFS and survival from the 3-and 6-month landmarks are shown in Tables SVII-SXIV. Mixed chimerism at 3 months was strongly associated with inferior PFS on UVA [HR 1Á93 (1Á24-3Á00), P = 0Á003; Fig 3] . At 3 months MVA showed trends toward inferior PFS for patients with mixed chimerism [HR 1Á74 (0Á94-3Á23), P = 0Á06] and in patients who received alemtuzumabbased therapy as their most recent treatment prior to alloSCT [HR 1Á75 (0Á95-3Á23), P = 0Á07]. On MVA, the only variable significantly associated with survival was age <60 years [HR 0Á56 (0Á34-0Á93), P = 0Á02]. At 6 months, 38/ 84 (45%) patients had mixed chimersm. On MVA, mixed chimerism [HR 3Á14 (1Á77-5Á58), P < 0Á001], receiving alemtuzumab as the most recent treatment prior to alloSCT [HR 2Á23 (1Á05-5Á15), P = 0Á037] and being refractory to most recent pre-transplant treatment [HR 1Á87 (1Á04-3Á36), P = 0Á037] were all significantly associated with inferior PFS from the 6-month landmark; receiving a sibling donor transplant was associated with superior PFS [HR 0Á56 (0Á33-0Á97), P = 0Á037]. On MVA, from the 6-month landmark, mixed chimerism [HR 3Á81 (1Á94-7Á48), P < 0Á001], receiving alemtuzumab as the most recent pre-transplant therapy [HR 2Á78 (1Á25-6Á17), P = 0Á012] and age ≥60 years [HR 0Á44 (1Á35-4Á76), P = 0Á02] were significantly associated with inferior survival. Seventy-nine patients had chimerism results at both 3 and 6 months; 9/41 (22%) patients with mixed chimerism at 3 months achieved ≥95% donor T-cell chimerism at 6 months; the remaining 32 patients had persistent mixed chimerism. Of 38 patients with full donor T-cell chimerism at 3 months, 35 remained full donor, while three developed mixed chimerism. There was no policy to give DLI for persistent mixed chimerism and only three patients received pre-emptive DLI for persistent mixed chimerism in the absence of disease relapse, although immunosuppression could be withdrawn according to physician preference.
Mixed chimerism at 6 months was associated with a significantly lower cumulative incidence of grade 2-4 acute GHVD (16Á3% vs. 51Á9%, P < 0Á001).
Immunomanipulation
Thirty-three patients were treated for either persistent or progressive disease with immunomanipulation. Seven patients who had tacrolimus withdrawn prior to planned DLI did not receive DLI: three achieved prompt CR without acute GVHD; four developed acute GHVD prior to planned DLI, all of whom subsequently achieved CR; six of seven developed chronic GVHD. Twenty-six patients received a total of 65 DLI: median number of DLI received was 2 (range 1-5); median dose was 1Á3 9 10 7 /kg (range 1 9 10 4 to 1Á6 9 10 8 ). Median time to first DLI was 389 days posttransplant (range 18-2036). Thirteen patients received DLI from unrelated donors and 13 from sibling donors (1 with single antigen mismatch). Per protocol, patients receiving DLI from unrelated donors received a lower initial dose (1 9 10 6 /kg) than those receiving DLI from matched sibling donors (1 9 10 7 /kg). Patients received dose-escalation by approximately 1 log every 6 weeks in the absence of GVHD or significant disease response, until the maximum dose of approximately 10 8 /kg. Twenty-two patients also received either rituximab (n = 21), or ofatumumab (n = 1), for two weekly doses prior to the first dose of DLI and two weekly doses post-DLI to enhance immunoreactivity. Thirty patients with progressive disease did not receive immunotherapy, for the following reasons: receiving alternative therapy, most commonly chemoimmunotherapy (n = 10), active GVHD (n = 7), Richter Transformation (n = 5), graft failure (n = 5) and other (n = 2).
Response to DLI and toxicity
Thirteen of 26 (50%) patients receiving DLI developed acute GVHD. Nine of 13 patients with unrelated and 4/13 with sibling donors developed acute GVHD, P = 0Á08. Post-DLI acute GVHD was fatal in four cases, all of whom received DLI from unrelated donors; two of these fatal cases developed after a single DLI at 10 6 /kg and two after the third dose of 10 8 /kg. The response to immune therapy was dichotomous. In addition to the seven patients that achieved CR after tacrolimus withdrawal alone, 9/26 patients achieved CR after DLI. There was only one stable partial response. The remaining 16 patients had progressive disease or died from acute GVHD-related complications prior to evaluation of response.
Of the 16 patients who achieved CR with immunomodulatory therapy, six are in ongoing CR at a median of 90 months (range 66-149 months). Seven patients subsequently relapsed; one, who relapsed 11 years after achieving CR, remains alive; the other six died: one patient developed Richter Transformation but achieved CR with chemoimmunotherapy; two patients died from GVHD, while one has been lost to follow-up. Thirteen of the 17 patients not achieving CR have died, two from GVHD, one from infection and 10 from CLL; four remain alive with disease after salvage therapy.
We performed landmark PFS analysis from the time of immunomodulation. Two patients were not evaluable due to early TRM. Evaluable patients achieving CR with immunotherapy had a superior subsequent PFS (median 60 months vs. 10 months, P < 0Á001) and survival (median 117 months vs. 32 months, P = 0Á006) to those who did not (Fig 4) . There was no difference in response according to whether patients had received in vivo T-cell depletion as part of transplant conditioning; 6/13 (46%) patients who had not received T-cell depletion achieved CR, while 10/18 (56%) patients who had received T-cell depletion responded (P = 0Á6). Patients with mixed chimerism at the time of immunomodulatory therapy showed a trend toward inferior CR rate; 6/14 evaluable patients (43%) achieved CR compared to 9/12 (75%) patients with full donor chimerism, P = 0Á1; in addition, patients with full donor chimerism at the time of immunomodulatory therapy had a superior PFS from the date of first DLI or tacrolimus withdrawal (median 32 months vs. 10 months, P = 0Á04), compared to those patients with mixed chimerism. Of patients with mixed chimerism at the time of immunomodulatory therapy, 8 of 14 converted to full donor chimerism: 6/8 (75%) achieved CR, compared to 0/6 who did not convert to full donor chimerism, P = 0Á005; 5/8 patients who converted to full donor chimerism developed acute GVHD, which was fatal in three cases and 7/8 developed cGHVD. In contrast only 1 of 6 patients who had persistent mixed chimerism developed acute and chronic GVHD; there was no TRM; all but one patient died from CLL.
Discussion
AlloSCT produces long-term disease-free remission in highrisk CLL. Our data confirm the importance of immunological control in achieving long-term disease control, given the high relapse risk conferred by mixed chimerism and the achievement of durable CR in approximately half of all patients after immunosuppression withdrawal with or without DLI.
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Having a CKT and receiving alemtuzumab as the most recent therapy prior to transplant were associated with inferior PFS, but not inferior survival, indicating that some early relapses were successfully salvaged. Patients with CKT had a high incidence of early relapse, accounting for the inferior PFS, which may have related to inadequate pre-transplant disease control. Inferior PFS in patients receiving alemtuzumab for CLL treatment as their most recent treatment prior to transplant was due to a combination of both increased TRM and increased relapse risk, probably related to increased immunosuppression and an association with post-transplant mixed chimerism and consequent failure of GVL. Pre-transplant B2M ≥ 4Á0 mg/l was associated with inferior survival. B2M level correlates with CLL protein synthesis (Vilpo et al, 1999) and markers of proliferation (Rossi et al, 2008 ). Thus, high B2M level may indicate inadequate pre-transplant disease control and contribute to poorer posttransplant outcomes (Gentile et al, 2009) ; this has also been seen in several non-transplant settings (Hallek et al, 1996 Tsimberidou et al, 2007; Tam et al, 2008; Wierda et al, 2009) . Additionally, high levels of B2M may be associated with immune dysfunction through impaired ability to generate monocyte-derived dendritic cells (Xie et al, 2003) ; it is thus possible that elevated B2M may contribute to failure of GVL-mediated disease control.
Post-transplant T-cell donor chimerism of ≤95% at both 3 and 6 months is associated with increased risk of relapse, probably due to failure of the GVL effect, resulting in excess mortality, predominantly early post-transplant. Lower incidence of acute GVHD in patients with mixed chimerism did not result in lower TRM. Mixed chimerism was more frequently seen in patients who received in vivo T-cell depletion as part of their transplant conditioning and in patients who received alemtuzumab as their most recent pre-transplant anti-leukaemic therapy. Given the association between mixed chimerism and inferior survival, anti-T-cell antibodies should be used only with caution in the setting of alloSCT for CLL.
Pre-emptive DLI effectively reduces relapse incidence in HL (Peggs et al, 2011) and FL (Thomson et al, 2010) . It is unclear from our data whether early, targeted intervention with immunosuppression reduction and/or DLI will reduce the incidence of disease relapse in patients with mixed chimerism and enhance long-term outcomes, as this was not routinely performed. Theoretically, pre-emptive DLI for mixed chimerism may be more effective than DLI given to treat clinical relapse, but this needs to be confirmed in a prospective study; the optimal timing of DLI would also need to be elucidated. Any enhanced disease control from early post-transplant immunomodulation would need to be balanced against increased risk of acute GVHD.
When DLI was given for relapse, the most important predictor of superior response rate and PFS was the presence of full donor T-cell chimerism; nonetheless, a sub-group of patients with mixed chimerism did achieve CR. Response was always associated with conversion to full-donor chimerism; however, this was associated with severe acute GVHD, which was fatal in three cases. All of the patients who developed fatal GVHD had received DLI from unrelated donors. The lower response rates to DLI in patients with mixed chimerism at the time of relapse and high rates of severe GVHD associated with conversion to full donor T-cell chimerism indicate that novel approaches are probably required to manage patients with persistent mixed chimerism post-transplant, particularly those who received alloSCT from unrelated donors. For those patients requiring DLI, enhancing the safety of DLI is a priority, particularly after unrelated donor transplant, where acute GVHD risk is higher. Transduction of donor T-cells with a an iCaspase-9 "suicide gene" has the potential to enhance safety; in a small study, rapid T-cell apoptosis after addition of the dimerizing agent AP1903 was seen, with concurrent resolution of GVHD (Di Stasi et al, 2011) .
Minimal residual disease (MRD) analysis using sensitive, standardized methods was not available at our institution until 2008. However, knowledge of level of CLL MRD and change over time would probably refine assessment of relapse risk; patients with mixed chimerism but with low and falling MRD levels may have lower relapse risk than a patient with high or rising levels of MRD (Farina et al, 2009; Dreger et al, 2010; Logan et al, 2013) . This information could be combined with an assessment of GVHD risk from DLI to inform clinical decisions. In the modern era, patients relapsing after alloSCT have a relatively favourable prognosis, due to the efficacy of novel agents such as ibrutinib in this setting (Rozovski et al, 2015) ; treatment with novel agents could potentially delay or obviate the need for DLI, particularly in patients with high risk of GVHD, such as those with unrelated donors. Maintenance therapy with ibrutinib is currently being explored in a multi-centre study; ibrutinib drives T H 1 differentiation in T-cells by inhibition of interleukin 2-inducible kinase (ITK) (Dubovsky et al, 2013) and has also been shown to reduce cGVHD in a murine model (Dubovsky et al, 2014) . The direct anti-leukaemic activity of ibrutinib may also allow time for effective GVL to become established and potentially delay the need for DLI. Finally, the precise role of alloSCT in patients with high-risk CLL, given the availability and success of novel therapies, such as ibrutinib and venetoclax (Roberts et al, 2016) remains to be defined and is the subject of much debate (Dreger et al, 2014) .
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